Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Disruption of a -35 kb Enhancer Impairs CTCF Binding and MLH1 Expression in Colorectal Cells.

Liu Q, Thoms JAI, Nunez AC, Huang Y, Knezevic K, Packham D, Poulos RC, Williams R, Beck D, Hawkins NJ, Ward RL, Wong JWH, Hesson LB, Sloane MA, Pimanda JE.

Clin Cancer Res. 2018 Sep 15;24(18):4602-4611. doi: 10.1158/1078-0432.CCR-17-3678. Epub 2018 Jun 13.

PMID:
29898989
2.

AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.

Unnikrishnan A, Vo ANQ, Pickford R, Raftery MJ, Nunez AC, Verma A, Hesson LB, Pimanda JE.

Leukemia. 2018 Apr;32(4):900-910. doi: 10.1038/leu.2017.340. Epub 2017 Nov 29.

3.

The Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune System.

Luo A, Leach ST, Barres R, Hesson LB, Grimm MC, Simar D.

Front Immunol. 2017 Apr 10;8:417. doi: 10.3389/fimmu.2017.00417. eCollection 2017. Review.

4.

Pathogenic germline MCM9 variants are rare in Australian Lynch-like syndrome patients.

Liu Q, Hesson LB, Nunez AC, Packham D, Hawkins NJ, Ward RL, Sloane MA.

Cancer Genet. 2016 Nov;209(11):497-500. doi: 10.1016/j.cancergen.2016.10.001. Epub 2016 Oct 11.

PMID:
27886675
5.

Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Ma SS, Henry CE, Llamosas E, Higgins R, Daniels B, Hesson LB, Hawkins NJ, Ward RL, Ford CE.

Virchows Arch. 2017 Jan;470(1):99-108. doi: 10.1007/s00428-016-2019-5. Epub 2016 Sep 8. Erratum in: Virchows Arch. 2016 Dec;469(6):717.

PMID:
27631337
6.

Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Ma SS, Henry CE, Llamosas E, Higgins R, Daniels B, Hesson LB, Hawkins NJ, Ward RL, Ford CE.

Virchows Arch. 2016 Dec;469(6):717. Epub 2016 Oct 29. No abstract available.

PMID:
27796585
7.

Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors.

Hesson LB, Ng B, Zarzour P, Srivastava S, Kwok CT, Packham D, Nunez AC, Beck D, Ryan R, Dower A, Ford CE, Pimanda JE, Sloane MA, Hawkins NJ, Bourke MJ, Wong JW, Ward RL.

Mol Cancer Res. 2016 Dec;14(12):1217-1228. Epub 2016 Sep 26.

8.

ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.

Ma SS, Srivastava S, Llamosas E, Hawkins NJ, Hesson LB, Ward RL, Ford CE.

BMC Cancer. 2016 Jul 20;16:508. doi: 10.1186/s12885-016-2576-7.

9.

Defining the criteria for identifying constitutional epimutations.

Sloane MA, Ward RL, Hesson LB.

Clin Epigenetics. 2016 Apr 18;8:39. doi: 10.1186/s13148-016-0207-4. eCollection 2016.

10.

PDGF-AB and 5-Azacytidine induce conversion of somatic cells into tissue-regenerative multipotent stem cells.

Chandrakanthan V, Yeola A, Kwan JC, Oliver RA, Qiao Q, Kang YC, Zarzour P, Beck D, Boelen L, Unnikrishnan A, Villanueva JE, Nunez AC, Knezevic K, Palu C, Nasrallah R, Carnell M, Macmillan A, Whan R, Yu Y, Hardy P, Grey ST, Gladbach A, Delerue F, Ittner L, Mobbs R, Walkley CR, Purton LE, Ward RL, Wong JW, Hesson LB, Walsh W, Pimanda JE.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):E2306-15. doi: 10.1073/pnas.1518244113. Epub 2016 Apr 4.

11.

An investigation of the potential for epigenetic inactivation by transcription read-through in a sporadic colorectal cancer.

Srivastava S, Ludwig AK, Wong JWH, Hesson LB.

Gene. 2016 Jul 1;585(1):154-158. doi: 10.1016/j.gene.2016.03.031. Epub 2016 Mar 22.

PMID:
27016300
12.

Understanding the Pathogenicity of Noncoding Mismatch Repair Gene Promoter Variants in Lynch Syndrome.

Liu Q, Thompson BA, Ward RL, Hesson LB, Sloane MA.

Hum Mutat. 2016 May;37(5):417-26. doi: 10.1002/humu.22971. Epub 2016 Mar 18. Review.

PMID:
26888055
13.

Obesity-induced sperm DNA methylation changes at satellite repeats are reprogrammed in rat offspring.

Youngson NA, Lecomte V, Maloney CA, Leung P, Liu J, Hesson LB, Luciani F, Krause L, Morris MJ.

Asian J Androl. 2016 Nov-Dec;18(6):930-936. doi: 10.4103/1008-682X.163190.

14.

A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome.

Liu Q, Hesson LB, Nunez AC, Packham D, Williams R, Ward RL, Sloane MA.

Carcinogenesis. 2016 Jan;37(1):10-17. doi: 10.1093/carcin/bgv154. Epub 2015 Oct 24.

PMID:
26498247
15.

The search for cis-regulatory driver mutations in cancer genomes.

Poulos RC, Sloane MA, Hesson LB, Wong JW.

Oncotarget. 2015 Oct 20;6(32):32509-25. doi: 10.18632/oncotarget.5085. Review.

16.

Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal Cancer.

Sloane MA, Nunez AC, Packham D, Kwok CT, Suthers G, Hesson LB, Ward RL.

JAMA Oncol. 2015 Oct;1(7):953-7. doi: 10.1001/jamaoncol.2015.1484.

PMID:
26181641
17.

Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression.

Hesson LB, Packham D, Kwok CT, Nunez AC, Ng B, Schmidt C, Fields M, Wong JW, Sloane MA, Ward RL.

Hum Mutat. 2015 Jun;36(6):622-30. doi: 10.1002/humu.22785. Epub 2015 Apr 17.

18.

Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas.

Zarzour P, Boelen L, Luciani F, Beck D, Sakthianandeswaren A, Mouradov D, Sieber OM, Hawkins NJ, Hesson LB, Ward RL, Wong JW.

Genes Chromosomes Cancer. 2015 May;54(5):303-14. doi: 10.1002/gcc.22243. Epub 2015 Feb 27.

PMID:
25726927
19.

The importance of distinguishing pseudogenes from parental genes.

Hesson LB, Ward RL.

Clin Epigenetics. 2014 Dec 31;6(1):90. doi: 10.1186/s13148-014-0033-5. eCollection 2014. No abstract available.

20.

Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients.

Sloane MA, Hesson LB, Nunez AC, Thompson BA, Ward RL.

Clin Epigenetics. 2014 Dec 13;6(1):32. doi: 10.1186/s13148-014-0032-6. eCollection 2014.

21.

Altered promoter nucleosome positioning is an early event in gene silencing.

Hesson LB, Sloane MA, Wong JW, Nunez AC, Srivastava S, Ng B, Hawkins NJ, Bourke MJ, Ward RL.

Epigenetics. 2014 Oct;9(10):1422-30. doi: 10.4161/15592294.2014.970077.

22.

Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia.

Sloane MA, Wong JW, Perera D, Nunez AC, Pimanda JE, Hawkins NJ, Sieber OM, Bourke MJ, Hesson LB, Ward RL.

Epigenetics. 2014 Aug;9(8):1092-100. doi: 10.4161/epi.29222. Epub 2014 May 16.

23.

Discrimination of pseudogene and parental gene DNA methylation using allelic bisulfite sequencing.

Hesson LB, Ward RL.

Methods Mol Biol. 2014;1167:265-74. doi: 10.1007/978-1-4939-0835-6_18.

PMID:
24823784
24.

The evidence for functional non-CpG methylation in mammalian cells.

Patil V, Ward RL, Hesson LB.

Epigenetics. 2014 Jun;9(6):823-8. doi: 10.4161/epi.28741. Epub 2014 Apr 9. Review.

25.

Establishing the clinical utility of epigenetic markers in cancer: many challenges ahead.

Zarzour P, Hesson LB, Ward RL.

Epigenomics. 2013;5(5):513-23. doi: 10.2217/epi.13.53.

PMID:
24059798
26.

Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure.

Hesson LB, Patil V, Sloane MA, Nunez AC, Liu J, Pimanda JE, Ward RL.

PLoS Genet. 2013;9(7):e1003636. doi: 10.1371/journal.pgen.1003636. Epub 2013 Jul 25.

27.

A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations.

Metz AJ, Bourke MJ, Moss A, Dower A, Zarzour P, Hawkins NJ, Ward RL, Hesson LB.

Eur J Gastroenterol Hepatol. 2013 Mar;25(3):319-26. doi: 10.1097/MEG.0b013e32835b57e7.

PMID:
23354161
28.

Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma.

Lau DT, Hesson LB, Norris MD, Marshall GM, Haber M, Ashton LJ.

Clin Cancer Res. 2012 Oct 15;18(20):5690-700. doi: 10.1158/1078-0432.CCR-12-0294. Epub 2012 Aug 28.

29.

Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosa.

Liu J, Hesson LB, Meagher AP, Bourke MJ, Hawkins NJ, Rand KN, Molloy PL, Pimanda JE, Ward RL.

Cancer Prev Res (Phila). 2012 Jul;5(7):921-9. doi: 10.1158/1940-6207.CAPR-11-0577. Epub 2012 May 18.

30.

A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines.

Hesson LB, Packham D, Pontzer E, Funchain P, Eng C, Ward RL.

Biol Proced Online. 2012 Apr 10;14(1):5. doi: 10.1186/1480-9222-14-5.

31.

Epimutations and cancer predisposition: importance and mechanisms.

Hesson LB, Hitchins MP, Ward RL.

Curr Opin Genet Dev. 2010 Jun;20(3):290-8. doi: 10.1016/j.gde.2010.02.005. Epub 2010 Mar 31. Review.

PMID:
20359882
32.

Identification of 5 novel genes methylated in breast and other epithelial cancers.

Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S, Tommasi S, Dobbins T, Gentle D, Euhus D, Lewis C, Dammann R, Ward RL, Minna J, Maher ER, Pfeifer GP, Latif F.

Mol Cancer. 2010 Mar 5;9:51. doi: 10.1186/1476-4598-9-51.

33.

The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.

Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F.

Mol Cancer. 2009 Jul 1;8:42. doi: 10.1186/1476-4598-8-42.

34.

RAN GTPase is a RASSF1A effector involved in controlling microtubule organization.

Dallol A, Hesson LB, Matallanas D, Cooper WN, O'Neill E, Maher ER, Kolch W, Latif F.

Curr Biol. 2009 Jul 28;19(14):1227-32. doi: 10.1016/j.cub.2009.05.064. Epub 2009 Jun 25.

35.

RASSF2 associates with and stabilizes the proapoptotic kinase MST2.

Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, Kolch W, Latif F.

Oncogene. 2009 Aug 20;28(33):2988-98. doi: 10.1038/onc.2009.152. Epub 2009 Jun 15.

36.

Epigenetic analysis of childhood acute lymphoblastic leukemia.

Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, Chiaramonte R, Brini AT, Griffiths M, Maher ER, Zabarovsky E, Latif F.

Epigenetics. 2009 Apr 1;4(3):185-93. Epub 2009 Apr 12.

PMID:
19430199
37.

Epigenetic markers in human gliomas: prospects for therapeutic intervention.

Hesson LB, Krex D, Latif F.

Expert Rev Neurother. 2008 Oct;8(10):1475-96. doi: 10.1586/14737175.8.10.1475. Review.

PMID:
18928342
38.

Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.

Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, Bieche I, Broggini M, Maher ER, Zabarovsky ER, Clark GJ, Latif F.

Oncogene. 2008 Mar 13;27(12):1805-11. Epub 2007 Sep 24.

39.

Evaluation of the 3p21.3 tumour-suppressor gene cluster.

Hesson LB, Cooper WN, Latif F.

Oncogene. 2007 Nov 15;26(52):7283-301. Epub 2007 May 28. Review.

PMID:
17533367
40.

The role of RASSF1A methylation in cancer.

Hesson LB, Cooper WN, Latif F.

Dis Markers. 2007;23(1-2):73-87. Review.

41.

The RASSF1A tumor suppressor activates Bax via MOAP-1.

Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, Calvisi D, Latif F, Clark GJ.

J Biol Chem. 2006 Feb 24;281(8):4557-63. Epub 2005 Dec 12.

42.

CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.

Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F.

Oncogene. 2005 Jun 2;24(24):3987-94.

PMID:
15806169
43.

Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.

da Silva NF, Gentle D, Hesson LB, Morton DG, Latif F, Maher ER.

J Med Genet. 2003 Nov;40(11):820-4.

44.

Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.

Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F, Kishida T, Grundy R, Yao M, Latif F, Maher ER.

Oncogene. 2003 Oct 2;22(43):6794-801.

PMID:
14555992

Supplemental Content

Loading ...
Support Center